NR3C2 and diabetic kidney disease: Additionally, finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has shown benefit in patients with diabetic kidney disease (DKD) and heart failure with preserved ejection fraction (HFpEF) [3–5].